Most therapies for osteoporosis slow the resorption of bone. Only one bone-forming agent, PTH 1–34 (which ... molecular mechanisms that mediate the anabolic effects of PTH and why individuals ...

Fracture prevention is the primary treatment goal for patients with osteoporosis. There are several treatments available nowadays with anabolic, antiresorptive or dual actions. A great number of ...

Given the wide pathophysiological spectrum of osteoporosis, however, some individuals might receive more benefit from a bone-forming agent than from antiresorptive therapy. Socrates Papapoulos ...

One growth driver is the increasing adoption of expensive anabolic therapies. The osteoporosis market is forecasted to grow from $10.5b in 2023 to $17.9b by 2033 at a compound annual growth rate ...